Rampart Investment Management Company LLC grew its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 219.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,153 shares of the medical equipment provider’s stock after purchasing an additional 7,665 shares during the period. Rampart Investment Management Company LLC’s holdings in Hologic were worth $417,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Hologic in the 1st quarter worth approximately $146,000. Synovus Financial Corp acquired a new stake in shares of Hologic in the 1st quarter worth approximately $164,000. NuWave Investment Management LLC acquired a new stake in shares of Hologic in the 4th quarter worth approximately $199,000. Homrich & Berg acquired a new stake in shares of Hologic in the 4th quarter worth approximately $219,000. Finally, IBM Retirement Fund acquired a new stake in shares of Hologic in the 1st quarter worth approximately $227,000. Institutional investors own 93.33% of the company’s stock.

In other Hologic news, VP Karleen Marie Oberton sold 12,196 shares of the stock in a transaction on Wednesday, May 2nd. The stock was sold at an average price of $40.00, for a total transaction of $487,840.00. Following the transaction, the vice president now owns 13,825 shares of the company’s stock, valued at approximately $553,000. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Charles J. Dockendorff purchased 13,000 shares of Hologic stock in a transaction on Thursday, March 15th. The shares were acquired at an average cost of $38.80 per share, for a total transaction of $504,400.00. The disclosure for this purchase can be found here. In the last three months, insiders have sold 29,303 shares of company stock worth $1,148,412. Corporate insiders own 0.88% of the company’s stock.

A number of equities research analysts recently weighed in on HOLX shares. Zacks Investment Research upgraded Hologic from a “hold” rating to a “buy” rating and set a $43.00 price target on the stock in a report on Tuesday, February 13th. Goldman Sachs Group cut Hologic from a “conviction-buy” rating to a “buy” rating and set a $43.00 target price on the stock. in a report on Monday, March 26th. BidaskClub upgraded Hologic from a “strong sell” rating to a “sell” rating in a report on Wednesday, April 18th. Needham & Company LLC reiterated a “buy” rating and set a $43.00 target price (down previously from $50.00) on shares of Hologic in a report on Tuesday, May 1st. Finally, Canaccord Genuity cut Hologic from a “buy” rating to a “hold” rating and lowered their target price for the company from $48.00 to $39.00 in a report on Thursday, May 3rd. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $44.87.

Shares of Hologic stock opened at $38.78 on Wednesday. Hologic, Inc. has a fifty-two week low of $35.10 and a fifty-two week high of $46.80. The firm has a market cap of $10.49 billion, a price-to-earnings ratio of 19.10, a price-to-earnings-growth ratio of 1.81 and a beta of 0.86. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.98 and a current ratio of 1.26.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.53 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.53. Hologic had a positive return on equity of 20.86% and a negative net margin of 4.15%. The company had revenue of $789.30 million for the quarter, compared to analyst estimates of $781.23 million. During the same quarter in the prior year, the company posted $0.50 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. analysts expect that Hologic, Inc. will post 2.23 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.